Interpace Diagnostics Announces Pricing of $13.7 Million Underwritten Public Offering of Common Stock and Common Warrants
PARSIPPANY, N.J., June 16, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for …